Fulcrum Wealth Advisors reduced its stake in Sellas Life Sciences by 33%, according to reports published late Tuesday and early Wednesday. The wealth advisor sold 35,998 shares and retains 73,253 shares valued at approximately $1.08 million.
The divestment occurs as Sellas nears the 80th event required to trigger the final analysis of its Phase 3 REGAL trial. This pivotal study evaluates a therapy for acute myeloid leukemia (AML) and represents a major catalyst for the company.
Sellas shares have declined 13% this month, despite a 3% gain on Tuesday. Retail sentiment on platforms like Stocktwits has turned bearish following the timing of the stake reduction ahead of the data readout.